Formulation Development

NANOSCALE COMPLEXES – A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex®

Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.

CELL CULTURE MARKET – 3D Cell Cultures: Next Generation & New Challenges

Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.

STEM CELL MARKET – Stem Cell Therapy to Redefine Regenerative Medicine

Jane C. Andrews, PhD, Frost & Sullivan Analyst, says faced with increasing challenges, such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself. With few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look toward regenerative medicine as a viable alternative.

EXCLUSIVE ONLINE CONTENT

11/1/2018

Verona Pharma Completes Enrollment in Phase 2 Clinical Trial

Verona Pharma plc recently announced it has enrolled the last patient in its Phase 2 clinical trial evaluating the effect of nebulized RPL554 as an add-on to dual therapy using long-acting anti-muscarinic/long-acting beta2-agonists (LAMA/LABA) and triple therapy (LAMA/LABA with an inhaled corticosteroid) in the maintenance treatment of patients with moderate to severe COPD.